IGF1 and cancer: Difficulties in designing potential isoform IGF1 agents arise due to the complexity of IGF1 gene splicing and the presence of different factors associated with post-translational modifications, as well as bioactivity of IGF1 and its isoforms in physiology [21,23] and pathology (including cancer) [49,112,165,179].